Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis

Cancer in Slovenia 2007. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2010.Search in Google Scholar

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl Med 2005; 352: 476-87.10.1056/NEJMra04095815689586Search in Google Scholar

Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008; 42: 207-14.10.2478/v10019-008-0019-zSearch in Google Scholar

Velenik V. Post-treatment surveillance in colorectal cancer. Radiol Oncol 2010; 44: 135-41.10.2478/v10019-010-0018-8342369922933905Search in Google Scholar

National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: colon cancer. V.3.2011 (on line). Avaible: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar

Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol 2010; 21: v93-7.10.1093/annonc/mdq22220555112Search in Google Scholar

Kohne CH. How to integrate molecular targeted agents in the continuum of care. Ann Oncol 2010; 21: vii134-9.10.1093/annonc/mdq37420943606Search in Google Scholar

Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.10.2478/v10019-009-0004-1Search in Google Scholar

Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transducting pathways in colorectal cancer-More than skin deep. J Clin Oncol 2005; 23: 5374-85.10.1200/JCO.2005.02.19415998904Search in Google Scholar

Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.10.1056/NEJMra0804588284369320018966Search in Google Scholar

Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9.10.1200/JCO.2008.18.728618757341Search in Google Scholar

Etienne-Grimaldi M-C, Formento J-L, Francoual M, François E, Formento P, Renée N, et al. K- Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008; 14: 4830-5.10.1158/1078-0432.CCR-07-490618676755Search in Google Scholar

Ličar A, Cerkovnik P, Ocvirk J, Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010, 36: 1137-44.10.3892/ijo_00000596Search in Google Scholar

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy- refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20.10.1001/jama.2010.1535Search in Google Scholar

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild- type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.10.1200/JCO.2007.14.7116Search in Google Scholar

Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466-74.10.1200/JCO.2009.23.3452Search in Google Scholar

Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Kohne C, et al. The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus folfiri. [Abstract]. Ann Oncol 2008; 19(Suppl 6): vi17-8.Search in Google Scholar

Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.10.1056/NEJMc0904160Search in Google Scholar

Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2010 Jul 20. [Epub ahead of print]10.1007/s12032-010-9631-zSearch in Google Scholar

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.10.1016/S1470-2045(10)70130-3Search in Google Scholar

Tejpar S, De Roock W. PIK13CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. Eur J Cancer 2009; 7: 322.10.1016/S1359-6349(09)71100-0Search in Google Scholar

Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a marker of resistence of cetuximab in chemorefractory metastatic colorectal cancer. [abstract] J Clin Oncol 2009; 27 (Suppl): 172.10.1200/jco.2009.27.15_suppl.4020Search in Google Scholar

Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.10.1093/annonc/mdq25820501503Search in Google Scholar

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.10.1016/j.ejca.2008.10.02619097774Search in Google Scholar

Kohne CH, Rougier P, Stroh C, Schlichting M, Bokemeyer C, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st- line treatment for metastatic colorectal cancer: A meta- analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO GI 2010 [abstract 406].Search in Google Scholar

Bookemeyer C, Kohne CH, Rougier P, Stroh C, Schlichting M, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st- line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]. J Clin Oncol 2010; 28 (Suppl): 3506.10.1200/jco.2010.28.15_suppl.3506Search in Google Scholar

Tejpar S, Bukemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E, et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first- line chemotherapy with or without cetuximab. ASCO 2011 [abstract 3511].10.1200/jco.2011.29.15_suppl.3511Search in Google Scholar

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21.10.1038/sj.bjc.6605177273683119603018Search in Google Scholar

Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR, et al. Activating K-ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumoursimplications for personalised cancer medicine. Br J Cancer 2010; 102: 1-11.10.1038/sj.bjc.6605534283756320147967Search in Google Scholar

Okines A, Del Puerto O, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-8.10.1038/sj.bjc.6605259276808619789532Search in Google Scholar

Terrebonne E, Smith D, Becouarn Y, Michel P, Guimbaud M, Fourrier- Reglat A, et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first- line therapy: results of the ETNA cohort study (abstract 3594). J Clin Oncol 2010; 28: (Suppl.):15s.10.1200/jco.2010.28.15_suppl.3594Search in Google Scholar

Ocvirk J, Rebersek M, Boc M. Bevacizumab in first- line therapy of meta-static colorectal cancer: A retrospective comparison of FOLFIRI and XELIRI. Anticancer Res 2011; 31: 1777-82.Search in Google Scholar

Wong R, Cunningham D, Barbachano Y, et al. A multicentric study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor- risk colorectal liver- only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-8.10.1093/annonc/mdq71421285134Search in Google Scholar

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.10.1056/NEJMoa080501919339720Search in Google Scholar

Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with or without cetuximab in the first- line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.10.1200/JCO.2008.20.839719114683Search in Google Scholar

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 1: 38-47.10.1016/S1470-2045(09)70330-4Search in Google Scholar

Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5- fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1-6.10.1038/sj.bjc.6605940299058320959822Search in Google Scholar